By vgreene, 8 July, 2020 Proposed mechanism: possible role for dysregulated bradykinin signaling in COVID-19 respiratory complications; mechanism incl inhibiting bradykinin generation by binding plasma kallikrein or inhibiting bradykinin receptors
By vgreene, 8 July, 2020 Ruxolitinib in Treatment of Severe Coronavirus Disease 2019 COVID 19 A Multicenter Single blind Randomized Controlled Trial
By vgreene, 8 July, 2020 Study considerations: randomized but single-blind; small sample size and early termination; excluded critically ill and mech vent pts; inconclusive results based on limited data and analysis
By vgreene, 8 July, 2020 No difference in total number of ADRs btwn 2 groups; no difference in median time of viral clearance; shorter median time of lymphopenia recovery in ruxolitinib group; cytokine levels significantly decreased in ruxolitinib group
By vgreene, 8 July, 2020 No difference in time to, or rate of, clinical improvement; significant CT improvement at day 14 w/ ruxolitinib (90% vs 62%); 28% overall mortality at day 28 (ruxolitinib 0% vs vitamin C 14%), no difference in cumulative incidence of death btwn 2 groups
By vgreene, 8 July, 2020 Prospective, single-blind, multicenter RCT; 41 pts (median age 63y) w/ severe COVID-19 randomly assigned 1:1 to receive ruxolitinib 5 mg PO bid + SOC (n=20) or vitamin C 100 mg PO bid + SOC (n=21); SOC incl antivirals, CS, and abx; median time btwn sx ons